Dr. Stephen Salloway, MD
Claim this profileButler Hospital
Studies Alzheimer's Disease
Studies Mild Cognitive Impairment
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Stephen Salloway, MD is currently running
BIIB080
for Alzheimer's Disease
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. Clinicians use the CDR-SB to measure several categories of dementia symptoms. The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of BIIB080. A description of how the study will be done is given below. Participants will receive either a low dose or high dose of BIIB080 or a placebo as an injection into the fluid around the spinal cord. A placebo looks like the study drug but contains no real medicine. The fluid around the spinal cord is called the cerebrospinal fluid. Participants will be in the study for 105 weeks, or a little over 2 years. This includes the screening and follow-up periods. Participants will be given BIIB080 or placebo once every 12 weeks for a total of 72 weeks. Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. After the screening period, most participants will visit the clinic every 6 weeks.
Recruiting0 awards Phase 24 criteria
Emtricitabine
for Alzheimer's Disease
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.
Recruiting0 awards Phase 18 criteria
More about Stephen Salloway, MD
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Stephen Salloway, MD has experience with
- BIIB080
- BIIB080-matching Placebo
- Emtricitabine
- Self-Guided Lifestyle Intervention
- Structured Lifestyle Intervention
- No Treatment
Breakdown of trials Stephen Salloway, MD has run
Alzheimer's Disease
Mild Cognitive Impairment
Cognitive Impairment
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen Salloway, MD specialize in?
Stephen Salloway, MD focuses on Alzheimer's Disease and Mild Cognitive Impairment. In particular, much of their work with Alzheimer's Disease has involved treating patients, or patients who are undergoing treatment.
Is Stephen Salloway, MD currently recruiting for clinical trials?
Yes, Stephen Salloway, MD is currently recruiting for 2 clinical trials in Providence Rhode Island. If you're interested in participating, you should apply.
Are there any treatments that Stephen Salloway, MD has studied deeply?
Yes, Stephen Salloway, MD has studied treatments such as BIIB080, BIIB080-matching placebo, Emtricitabine.
What is the best way to schedule an appointment with Stephen Salloway, MD?
Apply for one of the trials that Stephen Salloway, MD is conducting.
What is the office address of Stephen Salloway, MD?
The office of Stephen Salloway, MD is located at: Butler Hospital, Providence, Rhode Island 02906 United States. This is the address for their practice at the Butler Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.